Clinical Trials Browser

Interventional × Pathologic Complete Response × Breast × Clear all

NCT07586826 2026-05-14

N01-A-PICIT-GT

Phase 2 Recruiting

BreastClassical hematologyGynecologicThoracic

Pathologic Complete Response, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Thrombocytopenia, Endometrial Neoplasms

NCT01042379 2026-05-06

I-SPY

Phase 2 Recruiting

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT07066189 2025-10-29

Lifestyle, Exercise, And Nutrition (LEAN) Trial on Pathologic Complete Response in TNBC

Phase NA Recruiting

Pathologic Complete Response, Motor Activity, Triple Negative Breast Neoplasms

NCT04335669 2025-09-12

NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC

Phase 3 Active not recruiting

Pathologic Complete Response, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07164872 2025-09-10

Neoadjuvant Chemotherapy Combined With Preoperative Radiotherapy for Locally Advanced Breast Cancer

Phase NA Not yet recruiting

Pathologic Complete Response, Breast Neoplasms

NCT06927180 2025-06-23

SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC

Phase 2 Recruiting

Pathologic Complete Response, Breast Neoplasms

NCT05416164 2025-03-26

DESCARTES: De-ESCAlation of RadioTherapy in Patients With Pathologic Complete rESponse to Neoadjuvant Systemic Therapy

Phase NA Recruiting

Pathologic Complete Response, Breast Neoplasms

NCT05976815 2025-03-26

KEYMOVE

Phase NA Recruiting

Pathologic Complete Response, Breast Neoplasms, Motor Activity

NCT05918328 2025-03-07

Comparing the Efficacy of Nab-PH+Pyrrolitinib and TCbHP in the Neoadjuvant Treatment of HER2 Positive BC

Phase 2 Recruiting

Pathologic Complete Response, Breast Neoplasms

NCT05350722 2024-12-30

ABLATIVE-2

Phase NA Recruiting

Pathologic Complete Response, Breast Neoplasms

NCT06276868 2024-12-17

Darsilide Combined With AI, Trastuzumab and Patuzumab in the Neoadjuvant Treatment of HR+/HER2+ Breast Cancer

Phase 2 Recruiting

Pathologic Complete Response, Breast Neoplasms

NCT05659056 2024-04-16

Neoadjuvant Study With Pyrotinib and Trastuzumab and Abraxane in Patients With HER2-enriched Breast Cancer

Phase 2 Unknown

Pathologic Complete Response, Breast Neoplasms

NCT05474690 2024-02-26

A Study Comparing the Efficacy of TCbHP and ECHP-THP in the Neoadjuvant Treatment of HER2-positive Breast Cancer

Phase 3 Withdrawn

Pathologic Complete Response, Breast Neoplasms

NCT05103293 2023-12-27

PTC Guiding Neoadjuvant Treatment in Breast Cancer

Phase 2 Completed

BreastOther neoplasm

Pathologic Complete Response, Breast Neoplasms, Pathological Conditions, Signs and Symptoms

NCT05371860 2023-09-22

Radiation Omission in Patients With HER2 Overexpressing Tumors With Pathologic Complete Response

Phase 2 Withdrawn

Pathologic Complete Response, Breast Neoplasms

NCT05763992 2023-05-18

BREAKFAST-2

Phase 2 Unknown

Pathologic Complete Response, Breast Neoplasms, Fasting, Triple Negative Breast Neoplasms

NCT04781725 2021-11-17

INVINCIBLE TRIAL: Intratumoral INT230-6 in Breast Cancer

Phase 2 Unknown

Pathologic Complete Response, Breast Neoplasms

NCT04225858 2020-01-13

ASICS

Phase NA Not yet recruiting

Pathologic Complete Response, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01830244 2017-07-02

Neonab

Phase 2 Unknown

Pathologic Complete Response, Breast Neoplasms

NCT02511847 2016-04-15

Trial of Afatinib With Paclitaxel for Neoadjuvant Therapy of TNBC and Research of Biomarkers of Afatinib

Phase 2 Unknown

Pathologic Complete Response, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT00636441 2015-12-11

Trial to Evaluate Genomic Expression Profiles to Direct Preoperative Chemotherapy in Early Stage Breast Cancer

Phase 2 Terminated

56 enrolled 16 charts

Pathologic Complete Response, Breast Neoplasms

NCT02613026 2015-11-24

Comparative Analysis of the Efficacies in Neoadjuvant Chemotherapy of Breast Cancer

Phase 3 Completed

Pathologic Complete Response, Breast Neoplasms

NCT02059876 2014-02-12

Dose-dense (Biweekly) Carboplatin Plus Paclitaxel With or Without Trastuzumab as Neoadjuvant Treatment for Breast Cancer

Phase 2 Unknown

Pathologic Complete Response, Breast Neoplasms

NCT01956513 2013-10-08

ADC

Phase NA Withdrawn

Pathologic Complete Response, Breast Neoplasms

NCT01203267 2010-09-16

Weekly Paclitaxel Plus Carboplatin in Preoperative Treatment of Breast Cancer

Phase 2 Completed

Pathologic Complete Response, Breast Neoplasms